TY - JOUR T1 - A Treatment-Naïve Cellular Atlas of Pediatric Crohn’s Disease Predicts Disease Severity and Therapeutic Response JF - medRxiv DO - 10.1101/2021.09.17.21263540 SP - 2021.09.17.21263540 AU - Hengqi Betty Zheng AU - Benjamin A. Doran AU - Kyle Kimler AU - Alison Yu AU - Victor Tkachev AU - Veronika Niederlova AU - Kayla Cribbin AU - Ryan Fleming AU - Brandi Bratrude AU - Kayla Betz AU - Lorenzo Cagnin AU - Connor McGuckin AU - Paula Keskula AU - Alexandre Albanese AU - Maria Sacta AU - Joshua de Sousa Casal AU - Faith Taliaferro AU - Madeline Ford AU - Lusine Ambartsumyan AU - David L. Suskind AU - Dale Lee AU - Gail Deutsch AU - Xuemei Deng AU - Lauren V. Collen AU - Vanessa Mitsialis AU - Scott B. Snapper AU - Ghassan Wahbeh AU - Alex K. Shalek AU - Jose Ordovas-Montanes AU - Leslie S. Kean Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/22/2021.09.17.21263540.abstract N2 - Crohn’s disease is an inflammatory bowel disease (IBD) which most often presents with patchy lesions in the terminal ileum and colon and requires complex clinical care. Recent advances in the targeting of cytokines and leukocyte migration have greatly advanced treatment options, but most patients still relapse and inevitably progress. Although single-cell approaches are transforming our ability to understand the barrier tissue biology of inflammatory disease, comprehensive single-cell RNA-sequencing (scRNA-seq) atlases of IBD to date have largely sampled pre-treated patients with established disease. This has limited our understanding of which cell types, subsets, and states at diagnosis are predictive of disease severity and response to treatment. Here, through a combined clinical, flow cytometric, and scRNA-seq study, we profile diagnostic human biopsies from the terminal ileum of treatment-naïve pediatric patients with Crohn’s disease (pediCD; n=14) and from non-inflamed pediatric controls with functional gastrointestinal disorders (FGID; n=13). To fully resolve and annotate epithelial, stromal, and immune cell states among the 201,883 single-cell transcriptomes, we develop and deploy a principled and unbiased tiered clustering approach, ARBOL, yielding 138 FGID and 305 pediCD end cell clusters. Notably, through both flow cytometry and scRNA-seq, we observe that at the level of broad cell types, treatment-naïve pediCD is not readily distinguishable from FGID in cellular composition. However, by integrating high-resolution scRNA-seq analysis, we identify significant differences in cell states that arise during pediCD relative to FGID. Furthermore, by closely linking our scRNA-seq analysis with clinical meta-data, we resolve a vector of lymphoid, myeloid, and epithelial cell states in treatment-naïve samples which can distinguish patients with less severe disease (those not on anti-TNF therapies (NOA)), from those with more severe disease at presentation who require anti-TNF therapies. Moreover, this vector was also able to distinguish those patients that achieve a full response (FR) to anti-TNF blockade from those more treatment-resistant patients who only achieve a partial response (PR). Our study jointly leverages a treatment-naïve cohort, high-resolution principled scRNA-seq data analysis, and clinical outcomes to understand which baseline cell states may predict inflammatory disease trajectory.Competing Interest StatementJ.O.-M. reports compensation for consulting services with Cellarity and Hovione. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Hovione, Third Rock Ventures, Ochre Bio, FL82, and Dahlia Biosciences unrelated to this work. A.K.S. has received research support from Merck, Novartis, Leo Pharma, Janssen, the Bill and Melinda Gates Foundation, the Moore Foundation, the Pew-Stewart Trust, Foundation MIT, the Chan Zuckerberg Initiative, Novo Nordisk and the FDA unrelated to this work. Dr. Kean is on the scientific advisory board for HiFiBio and Mammoth Biosciences. She reports research funding from Kymab Limited, Magenta Therapeutics, BlueBird Bio, and Regeneron Pharmaceuticals. She reports consulting fees from Equillium, FortySeven Inc, Novartis Inc, EMD Serono, Gilead Sciences, Vertex Pharmaceuticals, and Takeda Pharmaceuticals. Dr. Kean reports grants and personal fees from Bristol Myers Squibb that are managed under an agreement with Harvard Medical School. L.A. is a consultant for Takeda Pharmaceuticals. G.W. reports Research funding from Abbvie, Jansen, Takeda, Allakos; SAB for Abbvie, Bristol Myers Squibb; DSMB for Abbvie. D.L.S., is the co-founder, CM, president of NiMBAL Health. S.B.S. declares the following interests: Scientific advisory board participation for Pfizer, Lilly, IFM therapeutics, Merck, Pandion, and Takeda Inc., and grant support from Pfizer, Novartis, Amgen, Takeda Consulting for Hoffman La Roche and Amgen. A.K.S., L.S.K., J.O.-M., H.B.Z., and B.A.D., are co-inventors on a provisional patent application relating to methods of stratifying and treating IBD.Clinical TrialNCT03369353Funding StatementJ.O.-M is a New York Stem Cell Foundation -- Robertson Investigator. J.O.-M was supported by the Richard and Susan Smith Family Foundation, the AGA Research Foundation's AGA-Takeda Pharmaceuticals Research Scholar Award in IBD -- AGA2020-13-01, the HDDC Pilot and Feasibility P30 DK034854, the Food Allergy Science Initiative, the Leona M. and Harry B. Helmsley Charitable Trust, The Pew Charitable Trusts Biomedical Scholars and The New York Stem Cell Foundation. L.S.K is supported by NIH P01 1P01HL158504, R01 5R01HL095791, U19 U19AI051731, and by the Helmsley Charitable Trust. V.N. was supported by the International mobility of research, technical and administrative staff of research organizations (CZ.02.2.69/0.0/0.0/18_053/0016981). A.K.S. was supported, in part, by the Searle Scholars Program, the Beckman Young Investigator Program, a Sloan Fellowship in Chemistry, and the NIH (5U24AI118672, 2R01HL095791). V.M. reports research support from Novartis. V.T. Is supported by ASTCT New Investigator Award and CIBMTR/Be the Match Foundation Amy Strelzer Manasevit Research Program Award. S.B.S. is supported by NIH grants P30 DK034854 and RC2 DK122532, and the Helmsley Charitable Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Pediatric patients less than 20 years of age with suspected inflammatory bowel disease were enrolled on the PREDICT Study (ClinicalTrials.gov# NCT03369353). Enrollment took place between November 9, 2017 to December 21, 2018 in accordance with the Fred Hutch Institutional Review Board (Protocol #9730, ethical approval given) with written informed consent and assent when applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and Code Availability Single-cell RNA-seq data can be visualized via the Single Cell Portal links for each atlas of FGID https://singlecell.broadinstitute.org/single_cell/study/SCP1422/predict-2021-paper-fgid and pediCD https://singlecell.broadinstitute.org/single_cell/study/SCP1423/predict-2021-paper-cd. The cell-by-gene matrices will be available with the peer-reviewed version of this manuscript. The raw human FASTQ files will be available from the Broad controlled access repository DUOS with the peer-reviewed version of this manuscript. Please contact the authors All original code has been assembled as the ARBOL package and deposited at GitHub and is publicly available together with this manuscript at: https://github.com/jo-m-lab/ARBOL and https://jo-m-lab.github.io/ARBOL/ARBOLtutorial.html. https://github.com/jo-m-lab/ARBOL https://singlecell.broadinstitute.org/single_cell/study/SCP1422/predict-2021-paper-fgid https://singlecell.broadinstitute.org/single_cell/study/SCP1423/predict-2021-paper-cd ER -